Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Illumina, Inc. develops, manufactures and markets integrated systems for the large scale analysis of genetic variation and biological function. The Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies.
Website: illumina.com



Growth: Pretty weak revenue growth rate 3.6%, there is slowdown compared to average historical growth rates 14.2%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +19.9%

Profitability: LTM EBITDA margin is positive, +3.0%. On average the margin is decreasing steadily. Gross margin is high, +60.2%. In the last quarter the company beat the estimated EPS, +300.0%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 32.4% higher than minimum and 76.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.2x by EV / Sales multiple , the company can be 51.6% overvalued

Insiders: For the last 3 months insiders bought company shares on $1.0 mln (0.005% of cap.)

Key Financials (Download financials)

Ticker: ILMN
Share price, USD:  (-1.3%)122.87
year average price 151.55  


year start price 204.39 2023-04-27

max close price 212.65 2023-05-24

min close price 92.79 2023-11-13

current price 122.87 2024-04-25
Common stocks: 157 100 001

Dividend Yield:  0.0%
FCF Yield LTM: 1.0%
EV / LTM EBITDA: 151.2x
Last revenue growth (y/y):  3.6%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  14.2%
Historical growth of EBITDA:  -21.3%
EV / Sales: 4.6x
Margin (EBITDA LTM / Revenue): 3.0%
Fundamental value created in LTM:
Market Cap ($m): 19 303
Net Debt ($m): 1 254
EV (Enterprise Value): 20 557
Price to Book: 3.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-19Zacks Investment Research

Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?

2024-04-12Reuters

EU approves Illumina's plan to divest cancer test maker Grail

2024-03-21The Motley Fool

Why Illumina Stock Zoomed Higher on Thursday

2024-03-21Reuters

EU court should back Illumina's appeal against EU review of Grail deal, court adviser says

2024-03-12Reuters

Exclusive: Icahn drops Illumina board challenge threat, sources say

2024-02-26The Motley Fool

Why Illumina Stock Mashed the Market on Monday

2024-02-20Zacks Investment Research

Illumina (ILMN) Rides on NGS Portfolio Expansion Amid Macro Woe

2024-02-09Zacks Investment Research

Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down

2024-02-08Seeking Alpha

Illumina, Inc. (ILMN) Q4 2023 Earnings Call Transcript

2024-02-08Zacks Investment Research

Illumina (ILMN) Reports Q4 Earnings: What Key Metrics Have to Say
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2023-01-01 2022-10-02
symbol ILMN ILMN ILMN ILMN ILMN ILMN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-16 2023-11-13 2023-08-10 2023-05-05 2023-02-17 2022-11-04
acceptedDate 2024-02-16 16:21:12 2023-11-09 18:30:59 2023-08-10 16:38:55 2023-05-05 16:32:21 2023-02-17 16:06:30 2022-11-03 19:06:27
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 1 122M 1 119M 1 176M 1 087M 1 083M 1 115M
costOfRevenue 447M 435M 444M 432M 411M 398M
grossProfit 675M 684M 732M 655M 672M 717M
grossProfitRatio 0.602 0.611 0.622 0.603 0.620 0.643
researchAndDevelopmentExpenses 329M 315M 358M 341M 346M 325M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 403M 303M 450M 378M 432M 146M
otherExpenses 34M -28M -1 000 000 -14M -41M 0
operatingExpenses 732M 618M 808M 719M 778M 471M
costAndExpenses 1 179M 1 053M 1 252M 1 151M 1 189M 869M
interestIncome 11M 13M 17M 17M 7M 3M
interestExpense 18M -19M -19M 14M 9M 6M
depreciationAndAmortization 107M 1 640M 24M 107M 106M 103M
ebitda 50M 886M -64M -64M -85M 4 149M
ebitdaratio 0.045 0.792 -0.054 -0.059 -0.078 3.721
operatingIncome -57M -754M -88M -64M -127M 4 046M
operatingIncomeRatio -0.051 -0.674 -0.075 -0.059 -0.117 3.629
totalOtherIncomeExpensesNet -111M -848M -13M -14M -15M -7 718M
incomeBeforeTax -168M -782M -89M -78M -168M -3 672M
incomeBeforeTaxRatio -0.150 -0.699 -0.076 -0.072 -0.155 -3.293
incomeTaxExpense 8M -28M 145M -81M -28M 144M
netIncome -176M -754M -234M 3M -140M -3 816M
netIncomeRatio -0.157 -0.674 -0.199 0.003 -0.129 -3.422
eps -1.110 -4.770 -1.480 0.020 -0.890 -24.310
epsdiluted -1.110 -4.770 -1.480 0.020 -0.890 -24.310
weightedAverageShsOut 159M 158M 158M 158M 158M 157M
weightedAverageShsOutDil 159M 158M 158M 158M 158M 157M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2023-01-01 2022-10-02
symbol ILMN ILMN ILMN ILMN ILMN ILMN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-16 2023-11-13 2023-08-10 2023-05-05 2023-02-17 2022-11-04
acceptedDate 2024-02-16 16:21:12 2023-11-09 18:30:59 2023-08-10 16:38:55 2023-05-05 16:32:21 2023-02-17 16:06:30 2022-11-03 19:06:27
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 1 048M 927M 1 553M 1 494M 2 011M 1 000M
shortTermInvestments 6M 6M 6M 24M 26M 41M
cashAndShortTermInvestments 1 054M 933M 1 559M 1 518M 2 037M 1 041M
netReceivables 752M 690M 741M 665M 671M 628M
inventory 587M 615M 617M 586M 568M 559M
otherCurrentAssets 216M 268M 306M 403M 285M 259M
totalCurrentAssets 2 609M 2 506M 3 223M 3 172M 3 561M 2 487M
propertyPlantEquipmentNet 1 551M 1 621M 1 707M 1 740M 1 744M 1 748M
goodwill 2 545M 2 527M 3 239M 3 239M 3 239M 3 238M
intangibleAssets 2 993M 3 029M 3 188M 3 237M 3 285M 3 335M
goodwillAndIntangibleAssets 5 538M 5 556M 6 427M 6 476M 6 524M 6 573M
longTermInvestments 196M 193M 0 0 0 0
taxAssets 0 -193M 0 0 0 0
otherNonCurrentAssets 217M 439M 417M 423M 423M 448M
totalNonCurrentAssets 7 502M 7 616M 8 551M 8 639M 8 691M 8 769M
otherAssets 0 0 0 0 0 0
totalAssets 10 111M 10 122M 11 774M 11 811M 12 252M 11 256M
accountPayables 245M 240M 244M 242M 293M 281M
shortTermDebt 86M 85M 750M 749M 1 248M 1 246M
taxPayables 79M 65M 84M 74M 97M 81M
deferredRevenue 252M 242M -750M 258M 245M 225M
otherCurrentLiabilities 987M 915M 2 059M 981M 987M 917M
totalCurrentLiabilities 1 570M 1 482M 2 303M 2 230M 2 773M 2 669M
longTermDebt 1 489M 2 187M 2 214M 2 234M 2 231M 1 243M
deferredRevenueNonCurrent 77M 73M 0 0 0 0
deferredTaxLiabilitiesNonCurrent 687M -73M 0 0 0 0
otherNonCurrentLiabilities 543M 555M 702M 654M 649M 104M
totalNonCurrentLiabilities 2 796M 2 742M 2 916M 2 888M 2 880M 1 856M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 687M 698M 726M 747M 744M 748M
totalLiabilities 4 366M 4 224M 5 219M 5 118M 5 653M 4 525M
preferredStock 0 0 0 0 0 0
commonStock 2M 2M 2M 2M 2M 2M
retainedEarnings -19M 157M 911M 1 084M 1 142M 1 281M
accumulatedOtherComprehensiveIncomeLoss -1 000 000 21M 12M -1 000 000 3M 39M
othertotalStockholdersEquity 5 763M 5 718M 5 630M 5 608M 5 452M 5 409M
totalStockholdersEquity 5 745M 5 898M 6 555M 6 693M 6 599M 6 731M
totalEquity 5 745M 5 898M 6 555M 6 693M 6 599M 6 731M
totalLiabilitiesAndStockholdersEquity 10 111M 10 122M 11 774M 11 811M 12 252M 11 256M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 10 111M 10 122M 11 774M 11 811M 12 252M 11 256M
totalInvestments 202M 6M 6M 24M 26M 41M
totalDebt 2 262M 2 187M 2 964M 2 983M 3 479M 2 489M
netDebt 1 214M 1 260M 1 411M 1 489M 1 468M 1 489M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2023-01-01 2022-10-02
symbol ILMN ILMN ILMN ILMN ILMN ILMN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-16 2023-11-13 2023-08-10 2023-05-05 2023-02-17 2022-11-04
acceptedDate 2024-02-16 16:21:12 2023-11-09 18:30:59 2023-08-10 16:38:55 2023-05-05 16:32:21 2023-02-17 16:06:30 2022-11-03 19:06:27
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -176M -3 816M -449M 3M -139M -3 816M
depreciationAndAmortization 107M 108M 108M 107M 106M 103M
deferredIncomeTax 9M 9M 12M -17M 17M -6M
stockBasedCompensation 94M 87M 106M 93M 100M 83M
changeInWorkingCapital 78M 1 000 000 26M 10M -14M -122M
accountsReceivables -9M 47M -79M 1 000 000 -25M 12M
inventory 27M 2M -31M -18M -8M -41M
accountsPayables 6M -6M 2M -46M 13M 1 000 000
otherWorkingCapital 54M -42M 134M 73M 6M -94M
otherNonCashItems 111M 3 750M 302M -186M 77M 3 706M
netCashProvidedByOperatingActivities 223M 139M 105M 10M 147M -52M
investmentsInPropertyPlantAndEquipment -51M -45M -47M -52M -88M -246M
acquisitionsNet -29M 0 0 0 -85M 0
purchasesOfInvestments 13M -8M -8M -3M -14M -4M
salesMaturitiesOfInvestments -18M 0 0 0 0 0
otherInvestingActivites 0 -1 000 000 18M -1 000 000 85M 0
netCashUsedForInvestingActivites -85M -54M -37M -56M -102M -250M
debtRepayment 0 -735M 0 -500M 0 0
commonStockIssued 0 30M 0 37M 0 30M
commonStockRepurchased -26M -2M 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -26M -2M -3M -10M 956M -2M
netCashUsedProvidedByFinancingActivities -26M -707M -3M -473M 956M 28M
effectOfForexChangesOnCash 9M -4M -6M 2M 10M -15M
netChangeInCash 121M -626M 59M -517M 1 011M -289M
cashAtEndOfPeriod 1 048M 927M 1 553M 1 494M 2 011M 1 000M
cashAtBeginningOfPeriod 927M 1 553M 1 494M 2 011M 1 000M 1 289M
operatingCashFlow 223M 139M 105M 10M 147M -52M
capitalExpenditure -51M -45M -47M -52M -88M -246M
freeCashFlow 172M 94M 58M -42M 59M -298M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-08 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-10 ET (fiscal 2023 q2)
2023 q1
2023-04-25 ET (fiscal 2023 q1)
2022 q4
2023-02-07 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-11 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-08 21:05 ET
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
2024-01-15 12:00 ET
Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world
2024-01-11 14:00 ET
BeniComp to Offer GRAIL’s Multi-Cancer Early Detection Test for Employee Health Screening
2024-01-11 14:00 ET
Illumina Ventures Labs Launches in the US and the UK to Enable More Rapid Value-Creation for Start-Ups Advancing Human Health
2024-01-09 14:00 ET
Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023
2024-01-05 14:15 ET
Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
2024-01-04 21:05 ET
Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024
2024-01-04 14:15 ET
The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk
2023-12-19 21:05 ET
Illumina To Webcast Upcoming Investor Conference
2023-12-17 19:37 ET
Illumina Announces Decision to Divest GRAIL
2023-12-11 17:57 ET
Illumina submits Form 10 to the Securities and Exchange Commission
2023-11-14 21:05 ET
Illumina To Webcast Upcoming Investor Conferences
2023-11-13 14:15 ET
Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries
2023-11-09 21:05 ET
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2023
2023-11-01 13:15 ET
Illumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors
2023-10-13 18:10 ET
Illumina responds to European Commission's divestiture order
2023-10-11 20:05 ET
Illumina Posted a Stewardship-Focused Presentation for Investors
2023-10-05 20:05 ET
Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023
2023-09-05 11:30 ET
Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer
2023-08-28 20:05 ET
Illumina To Webcast Upcoming Investor Conference
2023-08-17 13:15 ET
Illumina expands genomics capabilities in India with opening of Solutions Center
2023-08-11 20:05 ET
Illumina To Webcast Upcoming Investor Conference
2023-08-09 20:15 ET
Dr. Steven Barnard Appointed Chief Technology Officer
2023-08-09 20:05 ET
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2023
2023-07-25 13:15 ET
Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options
2023-07-18 20:05 ET
Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
2023-07-18 13:15 ET
The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck
2023-07-11 13:15 ET
Illumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery
2023-06-20 13:00 ET
Illumina Ventures to Launch Illumina® Ventures Labs
2023-06-11 12:00 ET
Illumina announces CEO transition plan
2023-06-05 13:15 ET
Illumina releases 2022 Corporate Social Responsibility Report
2023-06-02 11:30 ET
Illumina's Board of Directors elects two experienced Independent Directors to Board
2023-06-01 18:00 ET
Illumina unveils AI software to predict disease-causing genetic mutations in patients
2023-05-31 20:05 ET
Illumina to Host Third Annual Virtual ESG Investor Event on Monday, June 12, 2023
2023-05-30 13:15 ET
Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing
2023-05-25 18:17 ET
Illumina announces preliminary results of annual meeting
2023-05-24 18:00 ET
Pluton Biosciences Raises $16.5M Series A led by Illumina Ventures and RA Capital to discover and deploy microbes that will fight climate change
2023-05-18 14:51 ET
Illumina Board Chair issues letter to shareholders and urges shareholders to vote the WHITE proxy card FOR all nine of Illumina's nominees
2023-05-16 16:00 ET
Illumina's genomic technologies enable better pathogen preparedness and response
2023-05-12 23:12 ET
Leading Proxy Advisory Firm ISS Recommends Illumina Shareholders Vote "FOR" Eight of Illumina's Highly Qualified Director Nominees
2023-05-08 11:30 ET
Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's "Plan"
2023-05-02 13:15 ET
Illumina increases equitable access to STEM education, reaching over 1 million learners
2023-05-01 18:59 ET
Illumina Issues Shareholder Letter and Requests Shareholders Vote for the Illumina Director Nominees on the WHITE Proxy Card
2023-04-25 20:30 ET
Illumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth
2023-04-20 12:30 ET
Illumina Urges Shareholders to Vote the WHITE Proxy Card FOR all Nine of Illumina's Nominees
2023-04-18 13:00 ET
FirstHealth of the Carolinas to Offer GRAIL’s Galleri®, a Multi-Cancer Early Detection Blood Test
2023-04-12 13:17 ET
Illumina's cloud-based informatics programs recognized for robust, international data privacy protections
2023-04-11 13:15 ET
Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients
2023-04-05 13:15 ET
Illumina celebrates 25 years of innovation
2023-04-04 20:05 ET
Illumina to Announce First Quarter 2023 Financial Results on Tuesday, April 25, 2023
2023-04-04 13:15 ET
Illumina's revolutionary NovaSeq X exceeds 200th order milestone in first quarter 2023
2023-04-03 15:08 ET
Illumina Will Appeal FTC Decision in Federal Court, Will Seek US Resolution by Late 2023 or Early 2024
2023-03-30 13:15 ET
Illumina Files Preliminary Proxy, Urging Shareholders to Vote for Its Director Nominees and Withhold for Each Icahn Group Nominee
2023-03-29 12:00 ET
DNA Data Storage Alliance Announces Board Appointments
2023-03-27 13:15 ET
Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease
2023-03-24 19:59 ET
Illumina Issues Statement in Response to Carl Icahn's Letter
2023-03-20 11:30 ET
Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's Statements
2023-03-14 13:15 ET
Illumina launches its first product enabling long- and short-read sequencing on one instrument
2023-03-13 17:48 ET
Illumina Responds to Icahn Partners' Nomination of Directors
2023-02-27 21:10 ET
Illumina To Webcast Upcoming Investor Conference
2023-02-23 14:00 ET
John Hancock expands access to Galleri®, GRAIL's breakthrough cancer screening technology
2023-02-08 17:30 ET
Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute
2023-02-07 21:05 ET
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022
2023-02-01 14:15 ET
Illumina Appoints Joydeep Goswami Chief Financial Officer
2023-01-10 21:05 ET
Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
2023-01-09 14:00 ET
Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen
2022-12-19 21:05 ET
Illumina To Webcast Upcoming Investor Conference
2022-12-14 14:15 ET
Illumina Ranks Among Top Scores on Dow Jones Sustainability Index and CDP
2022-11-17 21:05 ET
GRAIL CCGA Discovery Results Published in Cancer Cell Reveal Methylation as Promising DNA Hallmark for Multi-Cancer Early Detection
2022-11-15 21:05 ET
Illumina To Webcast Upcoming Investor Conferences
2022-11-14 14:40 ET
Greenwood Genetic Center: Answering the Unanswered
2022-11-08 20:35 ET
New Virtual Lab for Students Opens Access to Next-Generation Sequencing
2022-11-08 14:30 ET
RNA Sequencing Critical to Identifying Key Fusions for Oncology Patients
2022-11-07 14:40 ET
Rarebase Is on the Hunt for Therapeutic Opportunities
2022-11-03 20:05 ET
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2022
2022-11-03 17:10 ET
Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States
2022-11-02 14:15 ET
ANAVASI DIAGNOSTICS ANNOUNCES NEWLY ELECTED OUTSIDE BOARD OF DIRECTORS
2022-11-02 12:00 ET
Twist Bioscience and Illumina Partner to Produce Robust Exome Panel to Advance Research
2022-11-01 13:10 ET
IGB Gene Drive Aims To Broaden Science Accessibility
2022-11-01 13:00 ET
Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States
2022-10-28 17:45 ET
Empowering the Disability Community at Illumina
2022-10-27 13:15 ET
Can Genomics Stop the World's Leading Cause of Death?
2022-10-25 17:55 ET
Francis deSouza Recognized as 3BL Media's Responsible CEO of the Year for Innovation and ESG Integration
2022-10-24 13:10 ET
Illumina To Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022
2022-10-18 10:00 ET
Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis
2022-10-17 20:05 ET
Illumina to Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022
2022-10-11 13:15 ET
Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery
2022-10-06 20:05 ET
Illumina to Announce Third Quarter 2022 Financial Results on Thursday, November 3, 2022
2022-09-29 21:00 ET
Illumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum
2022-09-29 17:00 ET
Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health
2022-09-26 13:15 ET
Illumina Genomics Forum Sold Out, Announces Opportunity to View Innovation Roadmap Session via Livestream
2022-09-22 15:00 ET
Henry Ford Health First in Michigan to Offer Multi-Cancer Early Detection Blood Test
2022-09-20 13:00 ET
John Hancock becomes the first life insurance carrier to offer access to GRAIL's multi-cancer early detection test to customers
2022-09-19 20:05 ET
Illumina to Host Upcoming Investor Day
2022-09-19 13:15 ET
Illumina Genomics Forum to Feature Nobel Laureate Frances Arnold as part of Distinguished Panel on How the Genomics Revolution Is Transforming Patient Care
2022-09-14 13:15 ET
Illumina Accelerator Invests in the Fifth Global Funding Cycle of Startups Advancing Breakthrough Therapeutics, Diagnostics, Women's Health, and Sustainable Agriculture Applications
2022-09-12 13:15 ET
Illumina Genomics Forum to Convene Leading Visionaries to Explore Architecting Health's Radically New Infrastructure
2022-09-08 10:15 ET
llumina Announces Opportunity to View Live Webcast of Illumina Genomics Forum Innovation Roadmap Session Followed by Investor Conference Call
2022-09-07 14:34 ET
Illumina Genomics Forum to Feature Diverse Lineup of Visionary Global Leaders
2022-09-06 11:25 ET
Illumina Intends to Appeal European Commission's Decision in GRAIL Deal
2022-09-01 17:00 ET
Administrative Law Judge Rules in Favor of Illumina in FTC Challenge of GRAIL Deal
2022-08-30 13:15 ET
Illumina Deepens Commitment to Customers in China with New Manufacturing Site
2022-08-29 13:15 ET
Illumina Genomics Forum to Feature Tennis Legend Chris Evert on the Role Genomics Played in her Cancer Fight
2022-08-22 13:15 ET
Illumina Genomics Forum to Feature 23andMe Co-founder and CEO Anne Wojcicki
2022-08-16 21:00 ET
Minderoo Foundation and Illumina Commit $40M AUD to Apply Advanced Genomics to Marine Conservation
2022-08-15 13:15 ET
Illumina Genomics Forum to Feature American Cancer Society CEO Karen Knudsen on the Future of Cancer Genomics
2022-08-11 20:05 ET
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2022
2022-08-08 13:15 ET
Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics
2022-08-04 12:00 ET
Illumina Ventures Announces Expansion of its Europe Team
2022-07-27 13:15 ET
Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities
2022-07-18 13:15 ET
Illumina Announces Inaugural Illumina Genomics Forum with a Conversation with Former U.S. President Barack Obama
2022-07-14 20:10 ET
Illumina to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
2022-07-14 08:00 ET
Illumina Among First in the World to Receive Approval of Science-Based Net-Zero Target
2022-06-28 13:00 ET
Community Health Network and Grail Partner to Offer Galleri® Multi-Cancer Early Detection Test in Central Indiana
2022-06-28 08:00 ET
Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health
2022-06-21 13:00 ET
GRAIL and Fountain Health Insurance Partner to Provide Coverage of Galleri® Multi-cancer Early Detection Test
2022-06-09 20:05 ET
JOYDEEP GOSWAMI APPOINTED INTERIM CFO; SAM SAMAD TO DEPART ILLUMINA
2022-06-07 13:15 ET
Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions
2022-06-02 17:10 ET
Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO
2022-05-31 13:00 ET
GRAIL Announces Collaboration With U.S. Department of Veterans Affairs and the Veterans Health Foundation to Evaluate Galleri® Multi-Cancer Early Detection Test
2022-05-24 12:00 ET
Illumina Ventures Announces Promotion and Additions to its Investment Team
2022-05-24 06:00 ET
Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy
2022-05-18 13:15 ET
Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care
2022-05-17 11:00 ET
GRAIL and Intermountain Healthcare Expand Partnership to Offer Galleri® Multi-Cancer Early Detection Blood Test to Eligible Patients in Utah
2022-05-12 15:00 ET
Comprehensive Study Establishes Cost of Late Detection and Treatment of Cancer
2022-05-05 20:05 ET
Illumina Reports Financial Results for First Quarter of Fiscal Year 2022
2022-05-05 13:15 ET
Illumina and Deerfield Management partner to accelerate drug development
2022-04-28 20:05 ET
Illumina To Webcast Upcoming Investor Conference
2022-04-25 06:00 ET
Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children
2022-04-14 20:05 ET
Illumina to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
2022-04-12 12:00 ET
Illumina Expands Access to Genomics in Latin America through New State-of-the-Art Solution Center
2022-04-11 14:29 ET
John Frank Joins Illumina as Chief Public Affairs Officer
2022-04-07 15:00 ET
Illumina Releases Annual Corporate Social Responsibility Report
2022-04-05 12:00 ET
DNA Data Storage Alliance Welcomes 50th Member
2022-03-16 13:15 ET
Illumina Accelerator Invests in Seven Omics Startups Advancing Breakthrough Therapeutics, Diagnostics, DNA Storage, Mental Wellness, and Sustainable Foods Applications
2022-03-15 07:00 ET
Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe
2022-03-14 13:15 ET
Illumina Welcomes Carissa Rollins as Chief Information Officer
2022-02-21 21:05 ET
Illumina To Webcast Upcoming Investor Conference
2022-02-15 16:00 ET
GRAIL and Point32Health Collaborate to Offer Galleri® Multi-Cancer Early Detection Blood Test
2022-02-10 21:05 ET
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2021
2022-02-03 21:05 ET
Illumina To Webcast Upcoming Investor Conferences
2022-02-03 06:00 ET
Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer
2022-01-24 13:30 ET
Illumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia
2022-01-20 21:05 ET
Illumina to Announce Fourth Quarter & Full Year 2021 Financial Results on Thursday, February 10, 2022
2022-01-10 21:21 ET
Illumina collaborates with Nashville Biosciences to accelerate medicines development
2022-01-10 21:19 ET
Illumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care
2022-01-10 21:19 ET
Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
2022-01-10 21:17 ET
Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership
2022-01-10 21:15 ET
Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference
2022-01-10 13:45 ET
Knight Cancer Institute at Oregon Health & Science University to Offer the Galleri® Multi-Cancer Early Detection Test
2022-01-05 21:15 ET
Illumina Enters Co-Development Partnership with SomaLogic
2022-01-04 14:00 ET
Illumina and Syapse Partner on Research to Evaluate Large Panel Biomarker Testing Patterns Across US Community Oncology Practices
2021-12-23 21:05 ET
Illumina To Webcast Upcoming Investor Conference
2021-12-14 20:21 ET
Gretel and Illumina Partner to Develop Synthetic Data for Genomic Research
2021-12-09 09:00 ET
Illumina Supports Norway's Pioneering Precision Medicine Study
2021-11-17 21:05 ET
Illumina and Sequoia Capital China Select First Startups to join Genomics Incubator in China
2021-11-16 16:15 ET
Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease
2021-11-04 20:05 ET
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2021
2021-11-03 20:05 ET
Illumina Supports Canada's Nationwide COVID-19 Genome Sequencing Initiative
2021-10-27 07:05 ET
Illumina Supports Israel's National Program to Accelerate Diagnoses of Critically-Ill Newborns with Suspected Genetic Disease
2021-10-20 22:00 ET
Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021
2021-10-14 23:35 ET
Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL
2021-10-13 21:00 ET
Illumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
2021-09-30 13:15 ET
Illumina Expands Presence in Latin America
2021-09-27 15:08 ET
Randomized trial demonstrates whole-genome sequencing leads to precision care for critically ill infants
2021-09-20 12:00 ET
Illumina Ventures Closes $325 Million Fund
2021-09-15 13:15 ET
Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle
2021-09-09 13:30 ET
Illumina Commits to Net Zero Global Greenhouse Gas Emissions by 2050
2021-08-30 21:00 ET
Illumina To Webcast Upcoming Investor Conference
2021-08-18 20:38 ET
Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test
2021-08-05 20:05 ET
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2021
2021-08-04 19:01 ET
Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India
2021-08-04 01:30 ET
Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India
2021-07-28 22:30 ET
Illumina to Webcast Upcoming Investor Conference
2021-07-22 16:49 ET
Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase
2021-07-19 11:07 ET
Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated precision medicine strategy
2021-07-13 21:00 ET
Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021
2021-06-10 12:00 ET
DNA Data Storage Alliance Publishes First White Paper, Launches Website
2021-06-01 07:05 ET
Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis
2021-05-31 20:00 ET
Illumina and Next Generation Genomic Partner to Launch VeriSeq™ NIPT Solution in Thailand
2021-05-27 21:00 ET
Illumina To Webcast Upcoming Investor Conference
2021-05-17 12:05 ET
Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development
2021-04-29 21:30 ET
Illumina To Webcast Upcoming Investor Conference
2021-04-29 13:05 ET
Illumina Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition
2021-04-28 13:05 ET
Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative
2021-04-27 20:05 ET
Illumina Reports Financial Results for First Quarter of Fiscal Year 2021
2021-04-22 20:05 ET
Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic
2021-04-20 10:30 ET
Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
2021-04-05 20:30 ET
Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021
2021-03-30 19:17 ET
Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
2021-03-18 20:05 ET
Illumina Announces Board Changes
2021-03-16 14:00 ET
Geneseeq Inks Deal with Illumina to Develop and Commercialize Comprehensive Cancer In-vitro Diagnostic NGS Kit in China
2021-03-11 21:05 ET
Illumina and Harvard Pilgrim Health Care Real-World Evidence Study Demonstrates Cost-Effectiveness of Offering NIPT to All Pregnant Women
2021-03-05 06:00 ET
Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia
2021-02-19 06:00 ET
Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases
2021-02-11 21:05 ET
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020
2021-02-10 12:00 ET
Illumina to Webcast Upcoming Investor Conference Presentations
2021-02-08 14:05 ET
Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle
2021-02-04 10:00 ET
Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium
2021-02-01 00:00 ET
Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China
2021-01-25 15:00 ET
Illumina to Announce Fourth Quarter & Full Year 2020 Financial Results on Thursday, February 11, 2021
2021-01-20 21:05 ET
Illumina Wins Patent Infringement Suit against BGI in the UK
2021-01-11 19:10 ET
New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale
2021-01-11 19:05 ET
Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling
2021-01-06 00:00 ET
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure
2020-12-22 12:00 ET
Illumina to Webcast Upcoming Investor Conference Presentations
2020-12-08 21:05 ET
Illumina and Harvard Pilgrim Health Care Expand Access to Whole-Genome Sequencing for Genetic Disease Testing
2020-11-18 12:00 ET
Illumina to Webcast Upcoming Investor Conference Presentation
2020-11-12 21:05 ET
Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit
2020-11-12 20:15 ET
Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA
2020-10-29 20:05 ET
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2020
2020-09-28 11:00 ET
Illumina to Announce Third Quarter 2020 Financial Results on Thursday, October 29, 2020
2020-09-23 20:05 ET
Illumina to Webcast Upcoming Investor Conference Presentation
2020-09-21 11:00 ET
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
2020-09-15 02:10 ET
Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System
2020-08-25 12:30 ET
Illumina Welcomes Kathryne Reeves as Chief Marketing Officer
2020-08-11 13:00 ET
Wouter Meuleman Promoted to Partner of Illumina Ventures
2020-08-07 12:55 ET
Illumina to Webcast Upcoming Investor Conference Presentation
2020-08-06 21:30 ET
Illumina Announces the NovaSeqTM 6000 v1.5 Reagent Kit Unlocking Deeper Discoveries with the $600 Genome
2020-08-06 20:05 ET
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2020
2020-07-16 20:05 ET
Illumina to Announce Second Quarter 2020 Financial Results on Thursday, August 6, 2020
2020-07-08 13:01 ET
Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases
2020-06-23 06:01 ET
Illumina Accelerator Welcomes First Global Cohort of Genomics Startups
2020-06-17 23:01 ET
Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale
2020-06-16 20:05 ET
Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies
2020-06-10 02:36 ET
Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test
2020-05-18 20:05 ET
Illumina, Inc. and the Illumina Corporate Foundation Commit $10 Million to COVID-19 Response and Research
2020-05-04 20:30 ET
Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development
2020-04-30 20:05 ET
Illumina Reports Financial Results for First Quarter of Fiscal Year 2020
2020-04-28 13:00 ET
Illumina’s Donation to the Africa Centre for Disease Control and Prevention Expands their Capability for Sequencing-Based COVID-19 Surveillance
2020-04-16 20:05 ET
Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19
2020-04-14 20:05 ET
Illumina Reports Preliminary Revenue for First Quarter of Fiscal Year 2020
2020-02-27 21:05 ET
Illumina Files Additional Patent Infringement Suit Against BGI in the U.S.
2020-02-12 21:22 ET
Illumina to Webcast Upcoming Investor Conference Presentations
2020-02-06 21:05 ET
Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors
2020-01-29 21:05 ET
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019
2020-01-13 21:05 ET
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
2020-01-13 17:06 ET
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
2020-01-13 16:55 ET
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
2020-01-10 13:00 ET
ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests
2020-01-02 21:05 ET
Illumina and Pacific Biosciences Announce Termination of Merger Agreement
2019-12-23 22:42 ET
Illumina to Webcast Upcoming Investor Conference Presentation
2019-12-03 13:00 ET
ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests
2019-11-20 21:05 ET
Illumina to Webcast Upcoming Investor Conference Presentations
2019-10-24 20:05 ET
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2019
2019-10-08 20:05 ET
Illumina to Announce Third Quarter 2019 Financial Results on Thursday, October 24, 2019
2019-10-07 20:05 ET
Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests
2019-09-30 12:55 ET
Illumina and Broad Institute Announce Agreement to Co-Develop Genomic Secondary Analysis Tools
2019-09-23 12:55 ET
Illumina Names Joydeep Goswami Senior Vice President of Corporate Development and Strategic Planning
2019-09-12 12:55 ET
Illumina Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Corporation
2019-04-25 20:12 ET
Helix Expands Focus to Population Health Solutions and Appoints Illumina Veteran Marc Stapley as CEO

SEC forms

Show financial reports only

SEC form 10
2024-02-16 00:00 ET
Illumina reported for 2023 q4
SEC form 8
2024-02-08 00:00 ET
Illumina published news for 2023 q4
SEC form 8
2024-02-08 00:00 ET
Illumina published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Illumina published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Illumina published news for 2023 q4
SEC form 10
2023-11-13 00:00 ET
Illumina published news for 2023 q3
SEC form 8
2023-11-09 16:07 ET
Illumina reported for 2023 q3
SEC form 10
2023-08-10 16:38 ET
Illumina published news for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Illumina published news for 2023 q2
SEC form 6
2023-08-09 16:21 ET
Illumina published news for 2023 q2
SEC form 6
2023-08-09 16:07 ET
Illumina reported for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Illumina published news for 2023 q2
SEC form 6
2023-07-18 16:27 ET
Illumina published news for 2023 q2
SEC form 6
2023-06-26 16:32 ET
Illumina published news for 2023 q1
SEC form 6
2023-06-13 16:59 ET
Illumina published news for 2023 q1
SEC form 6
2023-06-07 16:26 ET
Illumina published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Illumina published news for 2023 q1
SEC form 8
2023-04-25 00:00 ET
Illumina reported for 2023 q1
SEC form 10
2023-02-17 16:06 ET
Illumina reported for 2022 q4
SEC form 10
2023-02-17 00:00 ET
Illumina reported for 2022 q4
SEC form 6
2023-02-07 16:07 ET
Illumina reported for 2022 q4
SEC form 6
2023-02-07 07:57 ET
Illumina published news for 2022 q4
SEC form 8
2023-02-07 00:00 ET
Illumina reported for 2022 q4
SEC form 6
2023-02-01 17:20 ET
Illumina published news for 2022 q4
SEC form 8
2023-01-11 00:00 ET
Illumina published news for 2022 q4
SEC form 6
2023-01-10 19:06 ET
Illumina published news for 2022 q4
SEC form 6
2023-01-04 16:36 ET
Illumina published news for 2022 q4
SEC form 6
2022-12-13 16:31 ET
Illumina published news for 2022 q3
SEC form 6
2022-12-01 17:22 ET
Illumina published news for 2022 q3
SEC form 6
2022-11-14 16:32 ET
Illumina published news for 2022 q3
SEC form 10
2022-11-04 00:00 ET
Illumina reported for 2022 q3
SEC form 10
2022-11-03 19:06 ET
Illumina reported for 2022 q3
SEC form 6
2022-11-03 16:08 ET
Illumina published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Illumina reported for 2022 q3
SEC form 6
2022-10-05 19:45 ET
Illumina published news for 2022 q3
SEC form 6
2022-09-30 16:16 ET
Illumina published news for 2022 q2
SEC form 6
2022-09-16 16:45 ET
Illumina published news for 2022 q2
SEC form 6
2022-09-06 17:13 ET
Illumina published news for 2022 q2
SEC form 10
2022-08-11 16:14 ET
Illumina reported for 2022 q2
SEC form 6
2022-08-11 16:07 ET
Illumina published news for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Illumina reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Illumina reported for 2022 q2
SEC form 6
2022-07-14 16:02 ET
Illumina published news for 2022 q2
SEC form 6
2022-06-09 16:18 ET
Illumina published news for 2022 q1
SEC form 6
2022-05-27 16:36 ET
Illumina published news for 2022 q1
SEC form 6
2022-05-06 17:12 ET
Illumina published news for 2022 q1
SEC form 10
2022-05-05 16:09 ET
Illumina reported for 2022 q1
SEC form 6
2022-05-05 16:06 ET
Illumina published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Illumina reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Illumina reported for 2022 q1
SEC form 6
2022-04-14 16:29 ET
Illumina published news for 2022 q1
SEC form 6
2022-03-28 19:27 ET
Illumina published news for 2021 q4
SEC form 10
2022-02-18 15:11 ET
Illumina published news for 2021 q4
SEC form 10
2022-02-18 00:00 ET
Illumina published news for 2021 q4
SEC form 6
2022-02-10 16:07 ET
Illumina published news for 2021 q4
SEC form 8
2022-02-10 00:00 ET
Illumina published news for 2021 q4
SEC form 6
2022-01-11 17:23 ET
Illumina published news for 2021 q4
SEC form 8
2022-01-11 00:00 ET
Illumina published news for 2021 q4
SEC form 10
2021-11-05 00:00 ET
Illumina published news for 2021 q3
SEC form 10
2021-11-04 18:35 ET
Illumina published news for 2021 q3
SEC form 6
2021-11-04 16:11 ET
Illumina published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Illumina published news for 2021 q3
SEC form 6
2021-10-28 18:06 ET
Illumina published news for 2021 q3
SEC form 6
2021-10-14 21:08 ET
Illumina published news for 2021 q3
SEC form 6
2021-08-18 17:05 ET
Illumina published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
Illumina published news for 2021 q2
SEC form 10
2021-08-05 18:12 ET
Illumina published news for 2021 q2
SEC form 6
2021-08-05 16:11 ET
Illumina published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Illumina published news for 2021 q2
SEC form 6
2021-05-27 18:18 ET
Illumina published news for 2021 q1
SEC form 10
2021-04-28 00:00 ET
Illumina published news for 2021 q1
SEC form 10
2021-04-27 20:07 ET
Illumina published news for 2021 q1
SEC form 6
2021-04-27 16:10 ET
Illumina published news for 2021 q1
SEC form 8
2021-04-27 00:00 ET
Illumina published news for 2021 q1
SEC form 6
2021-04-19 19:37 ET
Illumina published news for 2021 q1
SEC form 6
2021-04-16 16:07 ET
Illumina published news for 2021 q1
SEC form 6
2021-04-05 16:32 ET
Illumina published news for 2021 q1
SEC form 6
2021-03-22 16:31 ET
Illumina published news for 2020 q4
SEC form 6
2021-03-18 16:40 ET
Illumina published news for 2020 q4
SEC form 6
2021-03-16 16:21 ET
Illumina published news for 2020 q4
SEC form 6
2021-03-12 16:07 ET
Illumina published news for 2020 q4
SEC form 6
2021-03-08 16:08 ET
Illumina published news for 2020 q4
SEC form 6
2021-03-04 17:28 ET
Illumina published news for 2020 q4
SEC form 10
2021-02-16 19:16 ET
Illumina published news for 2020 q4
SEC form 6
2021-02-11 16:11 ET
Illumina published news for 2020 q4
SEC form 6
2021-02-05 08:30 ET
Illumina published news for 2020 q4
SEC form 6
2021-01-12 17:27 ET
Illumina published news for 2020 q4
SEC form 6
2020-11-09 18:50 ET
Illumina published news for 2020 q3
SEC form 10
2020-10-29 20:14 ET
Illumina published news for 2020 q3
SEC form 6
2020-10-29 16:15 ET
Illumina published news for 2020 q3